Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc.

Bullboard Posts

Comment by topseekeron Jul 23, 2020 12:46pm

138 Views

Post# 31308560

RE:Some More DD

SoulTsunami wrote: Thank you B.O.B. over at https://investorshub.advfn.com/Algernon-Pharmaceuticals-Inc-AGNPF-30650/ for sharing this. Absolutely incredible: https://www.dovepress.com/small-cell-lung-cancer-growth-inhibition-synergism-between-nmda-recept-peer-reviewed-article-CPAA

Good catch and thanks for the sharing once again of real pertinent info on Ifenprodil. Gives some indication as to how phase 2b will play out for AGN.

In other words, I am buying more.

Best wishes to All, good health,

Sincerely,

Topseeker

Bullboard Posts

Full Circle Lithium goes global with its battery fire-fighter